评级与股价 - 美国银行证券将Cencora Inc评级调整为中性 维持持有建议 调整时股价为332.12美元 [1] - 评级调整当日 公司股价下跌1.99% 即下跌6.75美元 [1] - 公司股票52周价格区间为227.95美元至377.54美元 显示股价波动显著 [2] 市场表现与估值 - 公司当前市值约为643.7亿美元 [4] - 股票日交易量达227,149股 当日交易区间为329.10美元至337.31美元 [4] 增长驱动因素 - 华尔街分析师看好公司前景 主要驱动力为人工智能的采用和专科药物需求增长 [2] - 公司预计将从GLP-1药物更高的单位销量和销售额中受益 这对增长至关重要 [2] - 人工智能正在提升诊断和药物发现的效率与精准度 公司正利用AI改善运营并扩大市场影响力 [3] 行业背景 - 医疗行业正在经历转型 从防御性定位转变为增长引擎 [3]

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

As we enter a new year, the opportunity set in the stock market remains compelling. The US economy has proven more resilient than many expected, the artificial intelligence boom continues to gain momentum, and the rally in equities is broadening beyond the narrow leadership of the Magnificent Seven. Together, these dynamics are creating fertile ground for stock selection as we look ahead to 2026.One tool that has consistently stood out in this environment is the Zacks Rank. It remains one of the most effect ...

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer will participate in the 44th J.P. Morgan Healthcare Conference 2026 taking place from January 12–15, 2026 in San Francisco. Stefan Oelrich, Member of the Board of Management, Bayer AG, and President of Bayer's Pharmaceuticals Division, will present updates on the company's pharmaceutical growth strategy and pipeline advancements across its portfolio. The presentation will take place on Tuesday, January 13, 2026, from 11:15 to 11:55 PST. Investors, analysts. ...

The Tel Aviv Stock Exchange rose today. The Tel Aviv 35 Index rose 1.16% to 3,738.33 points - a new record, the Tel Aviv 125 Index rose 1.64% to 3,794.16 points; and the BlueTech Global Index rose 2.30% to 658.99 points. The All Bond corporate bond index rose 0.54% to 423.54 points. Turnover totalled NIS 5.91 billion in equities and NIS 6.84 billion in bonds. On the foreign exchange market, the representative shekel-dollar rate was set 0.723% lower from Friday, at NIS 3.203/$, and the representative shekel- ...

Novo Nordisk A/S (NYSE:NVO) on Monday said the Wegovy pill is now available, which was approved in December 2025.Novo Nordisk stock is charging ahead with explosive momentum. What’s fueling NVO momentum?Wegovy pill showed an average weight loss of about 17% (16.6%) when used along with a reduced-calorie diet and exercise, and if all patients stayed on treatment, compared to about 3% (2.7%) for placebo.When looking at the efficacy regardless of whether all patients stayed on treatment, an average weight loss ...

Key Points The end of a short-lived, COVID-related revenue surge has brought Pfizer's stock lower. But sellers have ignored all the developmental work this pharma icon has going on. At the very least, the drug stock’s current dividend payment is well protected. 10 stocks we like better than Pfizer › The average blue chip dividend stock's current yield is somewhere in the ballpark of 3% to 4%. Therefore, to see one paying out nearly 7% of its value is as suspicious as it is impressive. When the ...

Incyte Corporation (NASDAQ:INCY) on Monday shared topline results from the pivotal Phase 3 frontMIND trial of tafasitamab (Monjuvi/Minjuvi) combo as a first-line treatment for adults with newly diagnosed diffuse large B-cell lymphoma (DLBCL).The trial evaluated tafasitamab and lenalidomide in addition to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) compared to R-CHOP alone.The trial met its primary endpoint of progression-free survival (PFS). The trial also met its key seco ...

New analysis of a Phase 3 study of daridorexant shows that 50 mg improved both sleep and daytime functioning compared to placebo in women during menopausal transition ageBrigham and Women’s Hospital to study the effectiveness and safety of daridorexant for menopause-related insomnia symptoms Allschwil, Switzerland – January 5, 2026Idorsia Ltd (SIX: IDIA) announces the publication of “Efficacy and safety of daridorexant for the treatment of insomnia disorder in women during menopausal transition age: Insight ...

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...